May 12th 2024
Training at a major academic center offers firsthand exposure to groundbreaking 177Lu-PSMA-617 treatment for advanced prostate cancer.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
TALAPRO-2 Data Support Approval of Talazoparib/Enzalutamide in HRR-Mutant mCRPC
June 21st 2023Karim Fizazi, MD, discusses findings from the phase 3 TALAPRO-2 trial which support the recent FDA approval of talazoparib plus enzalutamide in homologous recombination repair gene-mutated metastatic castration resistant prostate cancer.
Watch
FDA Grants Approval to Talazoparib Plus Enzalutamide for HRR-Gene Altered mCRPC
June 20th 2023On the heels of an ASCO presentation of data from the phase 3 TALAPRO-2 trial, the FDA has granted approval to the study combination for the treatment of a metastatic castration-resistant prostate cancer subgroup.
Read More
Physicians Discuss the Addition of Cabazitaxel to Treatment in mCRPC
June 20th 2023In the first of a 2-part article series, Joshua Lang, MD, and live event participants discuss how the addition of cabazitaxel to the treatment of patients with metastatic castration-resistant prostate cancer can improve outcomes despite some challenging adverse events.
Read More
mCRPC: Practical Considerations for Real World Use of Lutetium Lu 177 Vipivotide Tetraxetan
June 19th 2023Comprehensive insight on the real-world use of lutetium Lu 177 vipivotide tetraxetan in metastatic castration-resistant prostate cancer management, given patient, disease, and logistical concerns.
Watch
Lutetium Lu 177 Vipivotide Tetraxetan in mCRPC: VISION and TheraP Trials
June 19th 2023Expert perspectives on the VISION and TheraP trials, which utilized lutetium Lu 177 vipivotide tetraxetan, also known as lutetium-177–PSMA-617, in the setting of metastatic castration-resistant prostate cancer.
Watch
Oncologists Encounter Challenges to Accessing PSMA-Targeted Therapy in Prostate Cancer
June 15th 2023Though the radioligand therapy lutetium Lu 177 vipivotide tetraxetan was approved in 2022 for PSMA-avid patients, several practical considerations have limited its use among patients with prostate cancer.
Read More
BRCA-Mutated mCRPC Has Worse Outcomes Than Non-BRCA HRR Population
June 4th 2023When comparing patients with metastatic castration-resistant prostate cancer who have homologous recombination repair deficiency mutations, those with BRCA mutations have worse outcomes compared to patients without the BRCA mutation in their disease.
Read More
Olaparib/Abiraterone Shows rPFS Benefit in mCRPC Regardless of HRR Status
May 31st 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Alicia K. Morgans, MD, MPH, discussed results of the phase 3 PROpel trial of patients with metastatic castration-resistant prostate cancer. This is the second of 2 articles based on this event.
Read More
Physicians Discuss When to Use a PARP Inhibitor in mCRPC
May 22nd 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Alicia K. Morgans, MD, MPH, and participants discussed situations when they would use a PARP inhibitor to treat patients with metastatic castration-resistant prostate cancer in the second or third line. This is the first of 2 articles based on this event.
Read More
ODAC Decision for Olaparib/Abiraterone in mCRPC Likely to Impact Forthcoming Studies
May 12th 2023In an interview with Targeted Oncology™, Andrew J. Armstrong, MD gave a first-hand perspective on the discussion held during the recent ODAC meeting and explained what the discussion and vote mean for the future of olaparib plus abiraterone in metastatic castration-resistant prostate cancer.
Read More
Racial Disparities Linked With High Rates of ADT-Related AEs in Prostate Cancer
May 9th 2023Significant differences in the incidence of genitourinary events, depression, and ischemic and thrombotic events were observed based on race among patients with prostate cancer after receiving androgen deprivation therapy.
Read More
FDA's ODAC Votes Yes to Olaparib Combination Being Restricted to BRCAm mCRPC
April 28th 2023The Oncologic Drugs Advisory Committee has discussed the approval application for olaparib plus abiraterone and prednisone or prednisolone for patients with metastatic castration-resistant prostate cancer and voted on its potential future.
Read More